NEWS & EVENTS

News & Events at Xyzagen

Stay up to date with Xyzagen’s latest breakthroughs, industry insights, and upcoming events shaping the future of drug development.

Events

May 8, 2025

Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025

At ARVO 2025, Xyzagen’s Christopher Crean presented long-acting anti-VEGF research highlighting pharmacokinetic insights for ocular therapies. Learn more:

December 16, 2024

Xyzagen Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024

At AES 2024, Xyzagen highlighted breakthrough Kv7 channel opener chemistry, presenting PK insights supporting novel epilepsy therapies. Learn more:

October 12, 2024

Xyzagen Presented Groundbreaking Kv7 Research at Society for Neuroscience Annual Meeting 2024

At SfN 2024, Xyzagen presented novel Kv7 channel opener prodrug research for advances in pain, epilepsy, & neurology. Learn more:

September 16, 2023

Xyzagen’s Founder, Christopher Crean, Presented Research on Kv7 Prodrugs at Kv7 Symposium

At the Kv7 Symposium, Xyzagen presented research on innovative Kv7 prodrugs highlighting advances in epilepsy & chronic pain. Learn more:

May 12, 2023

Xyzagen Presents Research on CPL-01 at ASPET 2023

At ASPET 2023, Xyzagen presented research on CPL-01, an extended-release ropivacaine, highlighting consistent PK for post-surgical pain. Learn more:

April 28, 2023

Xyzagen Presents Spring Discovery’s Research on Disulfiram at ARVO 2023

At ARVO 2023, Xyzagen presented Spring Discovery’s research on repurposing disulfiram for dry eye disease. Learn more:

December 15, 2022

Xyzagen Presented Promising Kv7 Channel Opener Prodrug Research at AES 2022

At AES 2022, Xyzagen presented Kv7 channel opener prodrug research highlighting seizure control & multi-route delivery for epilepsy. Learn more:

News

XYZ_Xyzagen Grows Team to Advance Quantitative Medicine & Genomics

March 30, 2024

Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities

Xyzagen announced strategic hires strengthening its quantitative medicine and genomics capabilities. Learn more:

February 20, 2024

Xyzagen Expands Services, Provides Drug Stability Capabilities

Xyzagen expanded its services to include early discovery drug stability capabilities, supporting formulation, PK, and preclinical development needs. Learn more:

January 1, 2024

Xyzagen Provides Dignify Therapeutics with Strategic Laboratory Solution

Xyzagen announced collaboration with Dignify Therapeutics to provide strategic in vivo solutions supporting nonclinical research. Learn more:

XYZ_Xyzagen Expands Pittsboro Lab and In Vitro ADME Services

October 1, 2023

Xyzagen Expands Laboratory in Pittsboro and Expands Services into In Vitro ADME Assays

Xyzagen expanded its Pittsboro laboratory, adding in vitro ADME and drug stability capabilities to support early drug discovery. Learn more:

July 27, 2023

Xyzagen Plays Critical Role in the Successful NDA Approval of XDEMVY

Xyzagen supported the NDA approval of XDEMVY, providing bioanalytical and pharmacokinetics expertise. Learn more:

XYZ_Xyzagen Grows Team, Expands Peptide LC-MS Expertise

July 13, 2023

Xyzagen Expands Expertise with New Team Members and Peptide LC-MS Capabilities

Xyzagen expands its expertise with new team members & peptide LC-MS capabilities, strengthening bioanalytical support for early discovery. Learn more:

XYZ_Christopher Crean Cover Feature in Pharmatech Outlook

November 11, 2020

Xyzagen’s founder and Principal Consultant, Christopher Crean, Featured in Pharmatech Outlook Bioanalytical Edition

Xyzagen’s founder was featured in Pharmatech Outlook’s Bioanalytical Edition, sharing insights on evolving drug discovery & CRO landscape. Learn more:

XYZ_Xenon Acquires Next-Gen Epilepsy Drug from 1st Order

April 26, 2017

Xenon Acquires Next-Generation Epilepsy Drug from 1st Order Pharmaceuticals

Xenon Pharmaceuticals acquired 1OP-2198, a next-generation epilepsy drug from 1st Order Pharmaceuticals. Learn more:

April 26, 2017

Xenon Expands Ion Channel Neurology Pipeline with Acquisition of XEN1101

Xenon Pharmaceuticals announced the acquisition of XEN1101, a next-generation Kv7 potassium channel modulator for the treatment of epilepsy. Learn more:

Our team is here to assist. Complete the form and we’ll be in touch shortly.

480 Hillsboro St., Ste 140 Pittsboro, NC 27312

LAB OPERATIONS: 919-726-2072

GENERAL INFO: [email protected]

BUSINESS DEV: [email protected]

Anonymous Animal Welfare Reporting Form

Get in touch

Name(Required)

First name Last name

Company/Organization(Required)

Company email(Required)

Phone

How can we help?

Message(Required)

CAPTCHA